Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.59, $1.42 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $300.4 million versus the consensus estimate of $185.4 million.

GUIDANCE:

Emergent BioSolutions sees FY2024 revenue of $1-1.1 billion, versus the consensus of $1.015 billion.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.